Table 1.
Patient and transplantation characteristics
| Donor KIR genotype |
P* | ||
|---|---|---|---|
| KIR3DS1 present, % | KIR3DS1 absent, % | ||
| No. of patients | 362 (33) | 725 (67) | |
| Disease | .38 | ||
| AML | 90 (25) | 216 (30) | |
| MDS | 54 (15) | 100 (14) | |
| Chronic myelogenous leukemia | 138 (38) | 252 (35) | |
| Acute lymphoblastic leukemia | 80 (22) | 157 (22) | |
| Median age, y (range) | 37.5 (0.8-60.8) | 35.3 (0.6-65.9) | .19 |
| Disease status | .38 | ||
| Early | 94 (26) | 187 (26) | |
| Intermediate | 185 (47) | 345 (45) | |
| Advanced | 83 (23) | 193 (27) | |
| HLA match | .70 | ||
| 10/10 | 219 (60) | 451 (62) | |
| 9/10; B-mismatch | 27 (7) | 59 (8) | |
| 9/10; C-mismatch | 116 (32) | 215 (30) | |
| GVHD prophylaxis | .78 | ||
| Cyclosporine A | 252 (70) | 499 (69) | |
| Non–cyclosporine A | 42 (12) | 78 (11) | |
| T-cell depletion | 68 (19) | 148 (20) | |
| Patient/donor sex | .86 | ||
| Male/male | 144 (40) | 279 (38) | |
| Male/female | 58 (16) | 127 (18) | |
| Female/male | 89 (25) | 186 (26) | |
| Female/female | 71 (20) | 133 (18) | |
| Patient/donor ethnicity | .51 | ||
| White | 332 (92) | 673 (93) | |
| Nonwhite | 30 (8) | 52 (17) | |
| Graft type | .91 | ||
| Bone marrow | 350 (97) | 700 (97) | |
| Peripheral blood | 12 (3) | 25 (3) | |
| CMV serostatus | .75 | ||
| Donor+/recipient+ | 67 (19) | 116 (16) | |
| Donor+/recipient− | 103 (28) | 212 (29) | |
| Donor−/recipient− | 130 (36) | 271 (37) | |
| Donor−/recipient+ | 59 (16) | 123 (17) | |
| Missing | 3 (1) | 3 (< 1) | |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; HLA, human leukocyte antigen; GVHD, graft-versus-host disease; and CMV, cytomegalovirus.
*
P values by χ2 test, except for age (2-sample t test).